Saxenda 2.4 mg: week 4, and the pediatric fallback dose
The short answer
Saxenda 2.4 mg daily is the week 4 dose on the FDA label, the last step before 3 mg. For adults, it's for titration (stepping up) only. Pediatric patients who don't tolerate 3 mg may have their maintenance dose reduced to 2.4 mg. The Saxenda price Novo Nordisk publishes is the list price, $1,349.02.
Key takeaways
- For adults, Saxenda 2.4 mg is the week 4 dose, for stepping up only. It isn't a dose to stay on.
- Pediatric patients who don't tolerate 3 mg may have their maintenance dose reduced to 2.4 mg daily.
- This isn't Wegovy 2.4 mg. Saxenda is liraglutide taken daily, and Wegovy is semaglutide taken weekly.
- A week at 2.4 mg uses nearly a whole pen.
- Novo Nordisk's list price is $1,349.02, and Saxenda isn't in the Medicare GLP-1 Bridge.
What the label says about Saxenda 2.4 mg
Once dailyNot a maintenance dose on the labelAt least 7 days before any increase
Week 4. In adults, lower dosages are for titration only; pediatric patients who do not tolerate 3 mg may have their maintenance dose reduced to 2.4 mg daily.
Table 1. Dosage Escalation Schedule: Week 4, 2.4 mg.
Comes as: Multi-dose single-patient-use pen, 18 mg per 3 mL pen (6 daily doses of 3 mg per pen; sold in cartons of 3 or 5 pens).
FDA label: Revised: 6/2026 (DailyMed version 22)
Saxenda dose schedule from the label
SaxendaRevised: 6/2026 (DailyMed version 22)
- 10.6 mg7 daysStart
- 21.2 mg7 days
- 31.8 mg7 days
- 42.4 mg7 daysThis page
- 53 mgongoingMaintenance dose
Put it on a calendar with the titration schedule builder. Only your prescriber decides when, and whether, your dose changes.
Supply per fill
| Form | Doses per device | Doses per fill | Days per fill | Fills per year |
|---|---|---|---|---|
| Multi-dose single-patient-use pen, 18 mg per 3 mL pen (6 daily doses of 3 mg per pen; sold in cartons of 3 or 5 pens) | 18 mg per pen | 30 | 30 | 12 |
Track run-out and refill dates with the supply tracker.
Saxenda 2.4 mg: every way to pay, cheapest first
This table uses the 2.4 mg dose. Prices can differ at other doses, so use the cost calculator for yours. Swipe the table sideways to see conditions and sources.
No price is listed for Saxenda 2.4 mg.
Savings-card and Medicare prices apply only if you are eligible. "From" prices that telehealth providers advertise are shown only at the lowest strength.
If you miss a dose of Saxenda
If you miss a daily shot, just take your next scheduled dose as normal; never take an extra or bigger dose to catch up.
If a dose is missed, resume the once-daily regimen as prescribed with the next scheduled dose. Do not administer an extra dose or increase the dose to make up for the missed dose.
If it has been more than 3 days since your last shot, restart at the 0.6 mg starting dose and work back up week by week to reduce stomach side effects.
If more than 3 days have elapsed since the last SAXENDA dosage, reinitiate SAXENDA at 0.6 mg daily and follow the dosage escalation schedule in Table 1, to reduce the risk of gastrointestinal adverse reactions associated with reinitiation of treatment.
Enter your own dates in the missed-dose helper. If you are unsure, call your prescriber or pharmacist; never take two doses to catch up.
Saxenda 2.4 mg means two different things depending on the patient’s age. For an adult, it’s seven days of stepping up. For a pediatric patient, it can be where treatment settles. The Saxenda guide explains the medicine overall, and this page covers the 2.4 mg dose.
Week 4 for adults
In the label’s step-up table, week 4 is 2.4 mg daily. It follows 1.8 mg in week 3 and leads to 3 mg from week 5 onward. This is the last of the four step-up weeks.
The label leaves adults no room to settle here. It says the recommended adult dosage is 3 mg daily, that lower dosages are for titration (stepping up) only, and that Saxenda is stopped if an adult can’t tolerate 3 mg. If the step to 2.4 mg itself isn’t tolerated, a delay of approximately one additional week can be considered, and that’s up to your prescriber.
The pediatric exception
Saxenda is approved for pediatric patients aged 12 years and older with body weight above 60 kg and obesity. Our label record for this step notes that pediatric patients who don’t tolerate 3 mg may have their maintenance dose, the dose they stay on, reduced to 2.4 mg daily. It’s the only dose below 3 mg that the label allows anyone to continue on.
The label’s pediatric trial ran for 56 weeks in patients aged 12 to 17. The estimated treatment difference in BMI SDS, a BMI score adjusted for age and sex, between Saxenda and placebo was -0.22. A young patient’s prescriber decides the dose they stay on.
Supply at 2.4 mg
One pen holds 18 mg. A week at 2.4 mg uses 16.8 mg, which is nearly a whole pen. On paper, a pen gives seven full doses of 2.4 mg, with a remainder smaller than one dose. For an adult passing through, week 4 uses about one pen. For a pediatric patient staying at 2.4 mg, that’s roughly a pen a week, and pens come in cartons of 3 or 5. Your pharmacist can work out the quantity your prescription needs. The supply tracker counts doses left in each pen.
Price and coverage at 2.4 mg
The published figure is the list price, $1,349.02, stated by Novo Nordisk without a supply period. Since the dose is a pen setting, what changes at 2.4 mg is how fast you use pens, not the price of a pen.
Coverage is limited whatever the dose. Every approved use of Saxenda is weight reduction, and CMS, the federal agency that runs Medicare, says Medicare and Medicaid generally don’t cover GLP-1 drugs for the weight loss indication. Saxenda also isn’t one of the products in the Medicare GLP-1 Bridge. For commercial plans, the Saxenda cost page lists the questions to ask.
Not the Wegovy 2.4 mg dose
People searching for “2.4 mg” often mean Wegovy. The two share a number and nothing else about the dose. Saxenda 2.4 mg is liraglutide taken daily. Wegovy 2.4 mg is semaglutide taken weekly, and it’s that medicine’s usual maintenance dosage. Neither label gives a way to convert between them.
Forms that carry 2.4 mg
The Saxenda pen only, as the fourth of its five settings. For calendar dates, use the titration schedule tool. The dosing guide explains step-up doses and maintenance doses across labels.
Frequently asked questions
Can adults stay on Saxenda 2.4 mg?
The label doesn't provide for it. For adults, it says the recommended dosage is 3 mg daily, lower dosages are for titration only, and Saxenda should be stopped if the patient can't tolerate 3 mg. The 2.4 mg maintenance option in our label record applies to pediatric patients only.
How is Saxenda 2.4 mg different from Wegovy 2.4 mg?
They're different medicines. Saxenda is liraglutide, injected every day, and 2.4 mg is its week 4 step-up dose. Wegovy is semaglutide, injected once a week, and 2.4 mg is its usual maintenance dose. They're different drugs with separate labels, and the matching number is a coincidence.
How many days does a Saxenda pen last at 2.4 mg?
A pen contains 18 mg of liraglutide. At 2.4 mg a day, that's seven full doses on paper, with a small amount left that's less than a dose. For an adult, 2.4 mg lasts one week on the label's schedule before the move to 3 mg.
What does the label say about Saxenda in teenagers?
Saxenda is approved for pediatric patients aged 12 and older with body weight above 60 kg and obesity. If they don't tolerate 3 mg, the maintenance dose may be reduced to 2.4 mg daily. In the label's 56-week pediatric trial, the estimated treatment difference in BMI SDS (a BMI score adjusted for age and sex) was -0.22 versus placebo.
Sources (6)
- 1.FDA label (DailyMed): Saxenda prescribing information, Instructions for Use
“It contains 18 mg of liraglutide, and you can select doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg and 3 mg.”
- 2.FDA label (DailyMed): Saxenda prescribing information, section 14.2
“The estimated treatment difference in BMI SDS reduction from baseline between SAXENDA and placebo was -0.22 with a 95% confidence interval of -0.37, -0.08; p=0.0022.”
- 3.Federal Register: Medicare and Medicaid Programs; Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly (proposed rule, 89 FR 99340)
“The statutory definition of a covered Part D drug at section 1860D-2(e)(2) of the Social Security Act (the Act) excludes certain drugs and uses—specifically, those that may be excluded by Medicaid under section 1927(d)(2) of the Act. This includes, at section 1927(d)(2)(A) of the Act, “agents when used for anorexia, weight loss, or weight gain.” Historically, drugs used for weight loss have been excluded from the definition of covered Part D drug, regardless of their use for treatment of individuals with obesity, and have been an optional drug benefit for Medicaid programs.”
- 4.CMS: BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model
“GLP-1 drugs for weight loss, along with lifestyle interventions, can help people improve their overall health, but GLP-1s are expensive and currently Medicare and Medicaid generally do not cover these drugs for the weight loss indication.”
- 5.
- 6.
